Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling

Hsieh,Chia-Jung; Kuo,Po-Lin; Hou,Ming-Feng; Hung,Jen-Yu; Chang,Fang-Rong; Hsu,Ying-Chan; Huang,Ya-Fang; Tsai,Eing-Mei; Hsu,Ya-Ling

doi:10.3892/ijo.2014.2769

Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling

Authors:
- Chia-Jung Hsieh
- Po-Lin Kuo
- Ming-Feng Hou
- Jen-Yu Hung
- Fang-Rong Chang
- Ying-Chan Hsu
- Ya-Fang Huang
- Eing-Mei Tsai
- Ya-Ling Hsu
View Affiliations

Affiliations: Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Department of Chinese Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C.
Published online on: November 21, 2014 https://doi.org/10.3892/ijo.2014.2769
Pages: 555-562

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The bone is the most common metastatic site of breast cancer. Bone metastasis causes pain, pathologic fractures, and severely reduces the quality of life. Breast cancer causes osteolytic bone metastasis, which is dependent on osteoclast-mediated bone resorption. While current treatments rely on palliative anti-resorptive agents, there is a need to develop a drug based on potential alternative therapies. This study is the first to determine that wedelolactone (WDL), a natural coumarin isolated from plants, can inhibit breast cancer-mediated osteoclastogenesis. Osteoclasts were generated from human CD14+ monocytes cultured with M-CSF/RANKL and WDL suppressed human osteoclast differentiation and activity in vitro in a dose-dependent manner. Moreover, WDL inhibited the upregulation of osteoclasts stimulated by MDA‑MB‑231 breast cancer cells. The activity of WDL on osteoclasts and breast cancer-mediated osteoclastogenesis was associated with the inhibition of Akt/mammalian target of the rapamycin signaling pathway (mTOR). Blocking Akt and mTOR by specific inhibitors significantly decreased osteoclast differentiation and bone resorption. Furthermore, WDL regulated breast cancer-enhanced interaction of osteoblasts and osteoclasts by decreasing M-CSF expression in MDA‑MB‑231-stimulated osteoblasts. Thus, this study suggests that WDL may be a potential natural agent for preventing and treating bone destruction in patients with bone metastasis due to breast cancer.

View Figures

View References

1	Akhtari M, Mansuri J, Newman KA, Guise TM and Seth P: Biology of breast cancer bone metastasis. Cancer Biol Ther. 7:3–9. 2008. View Article : Google Scholar
2	Rordorf T, Hassan AA, Azim H, et al: Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK intergroup. Breast. 23:511–525. 2014. View Article : Google Scholar : PubMed/NCBI
3	Rove KO and Crawford ED: Metastatic cancer in solid tumors and clinical outcome: skeletal-related events. Oncology. 23:21–27. 2009.
4	Weilbaecher KN, Guise TA and McCauley LK: Cancer to bone: a fatal attraction. Nat Rev Cancer. 11:411–425. 2011. View Article : Google Scholar : PubMed/NCBI
5	Gupta S, Gupta H, Mandhyan D and Srivastava S: Bisphophonates related osteonecrosis of the jaw. Natl J Maxillofac Surg. 4:151–158. 2013. View Article : Google Scholar
6	Verron E, Schmid-Antomarchi H, Pascal-Mousselard H, Schmid-Alliana A, Scimeca JC and Bouler JM: Therapeutic strategies for treating osteolytic bone metastases. Drug Discov Today. 19:1419–1426. 2014. View Article : Google Scholar : PubMed/NCBI
7	Roodman GD: Mechanisms of bone metastasis. N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
8	Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2:584–593. 2002. View Article : Google Scholar : PubMed/NCBI
9	Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science. 289:1508–1514. 2000. View Article : Google Scholar : PubMed/NCBI
10	Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
11	Lee ZH and Kim HH: Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun. 305:211–214. 2003. View Article : Google Scholar : PubMed/NCBI
12	Chen YC, Sosnoski DM and Mastro AM: Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 12:2152010. View Article : Google Scholar : PubMed/NCBI
13	Mountzios G, Dimopoulos MA, Bamias A, et al: Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 46:221–229. 2007. View Article : Google Scholar : PubMed/NCBI
14	McGrath EE: OPG/RANKL/RANK pathway as a therapeutic target in cancer. J Thorac Oncol. 6:1468–1473. 2011. View Article : Google Scholar : PubMed/NCBI
15	Azim HA, Kamal NS and Azim HA Jr: Bone metastasis in breast cancer: the story of RANK-ligand. J Egypt Nat Cancer Inst. 24:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
16	Patel M, Kadakia V and Mishra S: Simultaneous estimation of andrographolide and wedelolactone in herbal formulations. Indian J Pharm Sci. 70:6892008. View Article : Google Scholar : PubMed/NCBI
17	Roy RK, Thakur M and Dixit VK: Hair growth promoting activity of Eclipta alba in male albino rats. Arch Dermatol Res. 300:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
18	Singh B, Saxena AK, Chandan BK, Agarwal SG and Anand KK: In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. Indian J Physiol Pharmacol. 45:435–441. 2001.
19	Wagner H, Geyer B, Kiso Y, Hikino H and Rao GS: Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea. Planta Med. 370–374. 1986. View Article : Google Scholar : PubMed/NCBI
20	Lin FM, Chen LR, Lin EH, et al: Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis. 28:2521–2529. 2007. View Article : Google Scholar : PubMed/NCBI
21	Tewtrakul S, Subhadhirasakul S, Cheenpracha S and Karalai C: HIV-1 protease and HIV-1 integrase inhibitory substances from Eclipta prostrata. Phytother Res. 21:1092–1095. 2007. View Article : Google Scholar : PubMed/NCBI
22	Tsai CH, Lin FM, Yang YC, et al: Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res. 15:5435–5444. 2009. View Article : Google Scholar : PubMed/NCBI
23	Vender JR, Laird MD and Dhandapani KM: Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells. Neurosurgery. 62:1122–1128. 2008. View Article : Google Scholar : PubMed/NCBI
24	Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D and Ralston SH: Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther. 8:2339–2347. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sarveswaran S, Gautam SC and Ghosh J: Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCɛ without inhibiting Akt. Int J Oncol. 41:2191–2199. 2012.PubMed/NCBI
26	Sterling JA, Edwards JR, Martin TJ and Mundy GR: Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone. 48:6–15. 2011. View Article : Google Scholar
27	Furugaki K, Moriya Y, Iwai T, et al: Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis. 28:649–659. 2011. View Article : Google Scholar : PubMed/NCBI
28	Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY and Kuo PL: Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem. 286:37335–37346. 2011. View Article : Google Scholar : PubMed/NCBI
29	Takayanagi H: New immune connections in osteoclast formation. Ann NY Acad Sci. 192:117–123. 2010. View Article : Google Scholar
30	Yoneda T, Tanaka S and Hata K: Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop. 4:178–185. 2013. View Article : Google Scholar : PubMed/NCBI
31	Skeen JE, Bhaskar PT, Chen CC, et al: Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 10:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
32	Moon JB, Kim JH, Kim K, et al: Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J Immunol. 188:163–169. 2012. View Article : Google Scholar
33	Cao H, Zhu K, Qiu L, et al: Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem. 288:30399–30410. 2013. View Article : Google Scholar : PubMed/NCBI
34	Sugatani T and Hruska KA: Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem. 280:3583–3589. 2005. View Article : Google Scholar
35	Sanchez CP and He YZ: Bone growth during rapamycin therapy in young rats. BMC Pediatr. 9:32009. View Article : Google Scholar : PubMed/NCBI